Universitätsklinikum Hamburg-Eppendorf: Multiple Myeloma trials

The registry lists 11 Multiple Myeloma studies with Universitätsklinikum Hamburg-Eppendorf as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 9Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaNot yet recruitingNCT07600151Phase 1/2
• BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple MyelomaRecruitingNCT07564219Not applicable
• Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple MyelomaRecruitingNCT05853965Phase 1/2
• Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line TherapyTerminatedNCT05675319Phase 3
• Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple MyelomaCompletedNCT03700450Phase 2
• Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and DexamethasoneActive, not recruitingNCT03104842Phase 2
• Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal ImpairmentCompletedNCT02977494Phase 2
• Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple MyelomaCompletedNCT00781170Phase 2
• Dose-finding of Lenalidomide as Maintenance in Multiple MyelomaCompletedNCT00778752Phase 1/2
• Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple MyelomaCompletedNCT00777998Phase 2
• Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCTCompletedNCT00599495Phase 2